In December 2024 the FDA approved Eli Lilly's Zepbound (tirzepatide) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity - the first prescription medicine ever cleared for the sleep disorder. The indication was supported by two randomized, placebo-controlled SURMOUNT-OSA trials showing reductions in apnea-hypopnea events and body weight. The approval expands the peptide-based GLP-1/GIP agonist franchise beyond diabetes (Mounjaro) and obesity (Zepbound) into a cardiometabolic comorbidity that affects tens of millions of Americans, and it positions tirzepatide as a disease-modifying therapy rather than a cosmetic weight-loss drug.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.